Always a "Hold" -- neither a "Buy" or "Sell". . . In the context of other large cap pharma concerns -- here is the landscape, at the moment:
. . . .Jefferies Group has also taken action a number of other healthcare stocks recently. The firm raised its price target on shares of Pfizer Inc. from $40.00 to $42.00. They have a buy rating on that stock.
Also, Jefferies Group reiterated its hold rating on shares of Merck & Co., Inc.. They have a $63.00 price target on that stock, down previously from $69.00.
Finally, Jefferies Group reiterated its buy rating on shares of Eli Lilly and Co. They have a $87.00 price target on that stock, up previously from $80.00. . . .
Happy Friday, one and all. Be safe; be warm.
1 comment:
I think MRK is fully valued at current levels. I don't see any near-term drivers supporting a $69 price level. $63 is doable within normal volatility, but then so is $53.
Post a Comment